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INTRODUCTION
Transplant-associated microangiopathy (TAM) is
a serious complication of allogeneic stem cell trans-
plantation (alloTx). Although it is known that irradi-
ation induces endothelium damage, several previous
studies failed to correlate total-body irradiation
(TBI) with TAM development directly [1-3]. This
may be because of the dissimilar dose distribution
during TBI among treated individuals. We examined
retrospectively the incidence and risk factors of TAM
(grade .2) development in allografted patients with
lymphoid malignancies conditioned with TBI- or
non-TBI-based regimens. Additionally, we separately
tested the TBI-conditioned patients to identify spe-
cific factors influencing the TAM development
post-TBI.
During 2000 to 2006, 45 patients, aged 27 (range:
7-54) years, underwent alloTx for lymphoid malignan-
cies. Three patients allografted twice, because of re-
lapsed disease. All had been followed for at least 3
months. Forty donorswere siblings and 8 fullymatched
unrelated (MUD). Twenty-four patients were in com-
plete remission. Twenty-three were conditioned with
TBI-based and 25 with non-TBI-based regimen. An-
tithymocyte globulin (ATG) or MabCampath was
administered as part of conditioning regimen for pa-
tients allografted from any other donor than a sibling.
Cyclosporine (CSP) or Tacrolimus-based combina-
tions of immunosuppressive agents were used for acute
graft-versus-host disease (aGVHD) prophylaxis.
Thirty-two developed aGvHD (16 grade $II) and 37
of 45 evaluable patients with chronic GVHD
(cGVHD). TBI was performed using the 6 MV X-ray
beam generated by a 600C Varian linear accelerator.
The TBI technique consisted of 2 opposed anterior-1076posterior (AP) fields having the patient in a lateral decu-
bitus position. A total dose of 14.4Gywas delivered in 6
fractions twice a day over 3 days. Customized lung
blocks were used to reduce the lung dose to 12 Gy.
Table 1. Patients’ Characteristics
Conditioning Regimen
Total TBI non-TBI
Number of patients 45
Number of alloHCT* 48 23 25
Sex (M/F) 31/17 14/9 17/8
Median age (years) 27 27.6 25
Median follow-up (months) 13.5 13.3 13.7
Diagnosis
Acute lymphoblastic leukemia 31 16 15
Non-Hodgkin lymphoma 16 7 9
Hodgkin’s lymphoma 1 — 1
Disease status
Complete remission 24 12 12
Relapsed disease 12 7 5
Primary refractory disease 12 4 8
Donors
Siblings† 40 18 22
Matched unrelated 8 5 3
ABO incompatibility
Major 6 3 3
Minor 8 2 6
Major and minor 4 2 2
Conditioning regimens
TBI-Cy 17
TBI-Cy-ATG 5
TBI-Cy-VP16 1
BuCy2 17
BuCy2-Mabcampath 2
Thiotepa-BuCy2 3
Daunoxome-BuCy2 1
Thiotepa-Bu-Melphalan 1
Thiotepa-BuCy2-Mabcampath 1
Acute GVHD prophylaxis
CSP/MTX 37 16 21
CSP/MTX/FK506 1 1 —
CSP/MMF 1 — 1
CSP 1 1 —
FK506/MTX 7 4 3
FK506 1 1 —
Acute GVHD (grade I-IV) 32/45 18 14
Grade $ II 16/32 10 6
Chronic GVHD 37/45 19 18
Extensive 32/37 17 15
Limited 5/37 2 5
Body mass index
\25 kg/m2 8/22 8 —
$25 kg/m2 14/22 14 —
GVHD indicates graft-versus-host disease; TBI, total-body irridia-
tion; alloHCT, allogeneic hematopoietic cell transplants.
*Threepatientsunderwent a secondalloHCTbecauseofdisease relapse.
†One with antigen mismatch.
Letter to the Editor 1077Figure 1.Endothelium ‘‘dose sparing’’ because of the presence of excess adipose tissue in an obese patient compared to an equally sized (35 cmAP
diameter) low-fat patient. In low-fat patients (A) endothelium tissue lies less than 1 cm below the skin where, the % depth dose is at least 6%
higher than the midline dose (reference point for dose prescription). In obese patients (B) the first 4-5 cm below the skin is covered by fat tissue,
both anteriorly and posteriorly; therefore, endothelium lies at least 5 cm below the skin where the % dose distribution is only 3% to 4% higher
than the midline dose.The body mass index (BMI) was calculated by dividing
body weight (kg) by the square of the height (m2) [4].
The patients were classified in 2 groups with respect
to their BMI: those with BMI \25 (normal weight
and underweight) and those with BMI $25 (over-
weight and obese) (Table 1).
TAM was defined as the presence of a nonimmune
hemolytic anemia with elevated lactate dehydrogenase
(LDH), schistocytosis, platelet decrease, and was
staged according to Zeigler’s criteria [5].
Conditioning regimen, age, immunosuppressive
agents, GVHD, disease status, ABO incompatibility,
viral reactivation, recipient’s sex, and donor’s type
were examined as risk factors for TAM development
in univariate and multivariate analysis. To identify in-
dividually contributing factors for TAM post-TBI,
BMI was tested as a possible risk factor only for the
subgroup of 23 patients conditioned with TBI-based
regimen.
Statistical analysis was performed with the SPSS
package for Windows, version 9.0. Factors with P-
values \.05 were considered statistically significant.
Seventeen of 48 allografted patients developed TAM
grade $2 at a median time of 2.1 months, with an es-
timated probability of 40%. In univariate analysis,
TBI favored TAM development, and in multivariate
analysis female sex, aGVHD, tacrolimus administra-
tion, and advanced disease were identified as indepen-
dent significant factors. In multivariate analysis for the
separate group of 23 patients conditioned with TBI,
BMI \25 was found to be strongly associated with
TAMgrade.2 (P5 .0001). Significant adverse factors
were also viral reactivation and tacrolimus administra-
tion (P\ .01).DISCUSSION
TBI is known to cause endothelial damage, and has
been implicated for TAM development [1-3,5]. The
reported incidence of TAM ranges from 0.5% to
75%, implying at least partially, the lack of standard
definition criteria and differences in patient character-
istics, GVHD prophylaxis, and conditioning regimens
[3,6].
A relatively uniform patient populationwas studied
with respect to disease type, and this allowed us to de-
termine more accurately the role of conditioning regi-
men in TAM incidence. The 5-year cumulative
incidence of TAM grade .2 was 40%. In agreement
with several previous reports we also identified as inde-
pendent risk factors the presence ofGVHDand female
gender [7,8]. In univariate analysis, TBI was shown as
a significant factor for TAM (P 5 .023) development,
but it did not retain its significance inmultivariate anal-
ysis. Although the small number of patients in our study
could be etiologically associated with this statistical
discrepancy, a larger series also did not document the
significance of TBI for TAM development [3].
It has been shown that irradiation injures the vascu-
lar endothelium; however, the failure to prove a direct
correlationofTBIwithTAMcouldbe attributed todif-
ferences in dose distribution duringTBI among treated
individuals. As the target dose of TBI is being pre-
scribed in themidlineof thebody and thehomogeneous
distribution of irradiation directly depends on patient’s
AP diameter, we hypothesized that the depth of adipose
tissuemayaffect thedistributionof radiationdose by in-
creasing theAPdiameter.BMI, althoughnot absolutely
precise, is the most widely used measure to detect the
1078 Letter to the Editorexcess of body adiposity. In a study by Romero-Corral
et al. [9] it was demonstrated that BMI $25 had
a good sensitivity to detect body fat percentage.
Our TBI-conditioned patients with BMI \25
(normal-weight and underweight individuals) were in
higher risk for TAM development compared to those
with BMI $25 (overweight and obese individuals).
TBI, when performed with 2 opposed anterior-poste-
rior fields of 6 MV X-rays, yields the maximum dose
into both beam entry surfaces and decreases smoothly,
toward the midline. As it is shown in Figure 1, adipose
tissue, which is less vascular than other tissues (ie, mus-
cles) receives greater radiation dose because of its
proximity to the beam entry, compared to underlying
more vascular tissues. Therefore, we hypothesized
that fat could act protectively; because the vascular
endothelium of tissues underneath the adipose tissue
receives 2% to 3% lower radiation dose in overweight
and obese compared to normal and underweight indi-
viduals. Although this dose difference could be consid-
ered ‘‘marginal,’’ it could still be responsible for TAM
occurrence, if it exceeds a yet undefined threshold dose
for TAM development.
Our findings demonstrate that additional individ-
ual factors such as excess adipose tissue may affect
TAMpost-TBI and emphasize the necessity to explore
safer and more efficacious TBI procedures. Given that
the heterogeneous distribution of irradiation influ-
ences TBI toxicity, the use of higher energy X-rays
(.10 MV), because of their increased penetration,
could achieve a more homogeneous distribution, re-
sulting possibly in lower endothelium damage.
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